Home › Research › Drug development
Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials
Cai W, Zhang H, Wu Y, Yao Y, Zhang J.. Frontiers in aging neuroscience, 2025-01-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Tau protein aggregation, a key pathological feature of AD, is closely associated with neurodegeneration and cognitive decline. By investigating the effects of monoclonal antibodies on cognitive function, disease progression, and overall quality of life in patients with AD, which can provide valuable insights into their potential as a therapeutic option for this devastating neurodegenerative disorder. Results This study encompassed six RCTs involving 2,193 patients. Tilavonemab showed a lower incidence of AE, SAE, fall, and urinary tract infections than placebo, and the differences were statistically significant. Most safety analysis results showed no statistical difference. Conclusion The results indicated that anti-tau protein monoclonal antibodies, such as Semorinemab and Tilavonemab, showed promise in terms of efficacy and safety for managing AD. Further studies are needed to confirm these findings, assess long-term effects, and refine treatment protocols.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cai, W., Zhang, H., Wu, Y., Yao, Y., & Zhang, J. (2024). Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2024.1465871
Vancouver
Cai W, Zhang H, Wu Y, Yao Y, Zhang J. Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in aging neuroscience. 2024. doi:10.3389/fnagi.2024.1465871. PMID: 39945003.
BibTeX
@article{cai2024-39945003,
author = {Cai, W. and Zhang, H. and Wu, Y. and Yao, Y. and Zhang, J.},
title = {{Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials}},
journal = {Frontiers in aging neuroscience},
year = {2024},
doi = {10.3389/fnagi.2024.1465871},
pmid = {39945003},
url = {https://doi.org/10.3389/fnagi.2024.1465871}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Tau protein aggregation, a key pathological feature of AD, is closely associated with neurodegeneration and cognitive decline.
- By investigating the effects of monoclonal antibodies on cognitive function, disease progression, and overall quality of life in patients with AD, which can provide valuable insights into their potential as a therapeutic option for this devastating neurodegenerative disorder.
- Results This study encompassed six RCTs involving 2,193 patients.
- Tilavonemab showed a lower incidence of AE, SAE, fall, and urinary tract infections than placebo, and the differences were statistically significant.
- Most safety analysis results showed no statistical difference.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Participants2,193
- Effect size79.5%
- Evidence strengthHigh
How this study scored 86/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 50 of the 58 points we could judge it on, which is 86 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,193 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39945003) |
| Free to read | 2 / 2 | Free to read |
| Points | 50 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 50 of the 58 points we could judge it on is 86 out of 100. |
| Total | 86 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “randomized-controlled-trial”
16 studies in the library carry the topic tag “randomized-controlled-trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 16 tagged studies.